 |
Photo = Samsung Electronics |
[Alpha Biz= Reporter Kim Sangjin] On December 18, Samsung announced an investment in the U.S. bio venture company Generate Biomedicines through its Life Science Fund, which was established to develop new technologies and businesses in the life sciences field. Generate Biomedicines uses generative artificial intelligence (AI) to significantly reduce the drug development timeline.
The Life Science Fund is a venture capital fund jointly created by Samsung C&T, Samsung Biologics, and Samsung Bioepis, with a total investment of KRW 240 billion. The fund is managed by Samsung Venture Investment.
According to Samsung, Generate Biomedicines specializes in protein design technologies using generative AI and machine learning. The company is also focused on accumulating large-scale data to enhance AI model performance and increase the success rate of drug development.
One of its key innovations is Chroma, its proprietary generative AI program, which allows the rapid design of de novo proteins with specific characteristics and functions. Generate Biomedicines is currently developing drugs for a variety of diseases, including cancer, immune diseases, and infectious diseases.
Through this investment, Samsung plans to establish strategic partnerships for production ecosystems, such as contract manufacturing organizations (CMO), and collaborate on co-developing new drugs. Samsung aims to accelerate AI-based business growth through these multifaceted partnerships.
Alphabiz Reporter Kim SangJin(letyou@alphabiz.co.kr)
